MDT-AP-3283
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 2.3
- sex
- F
- new_clusters
- C4
- umap1_2d
- 2.455415288
- umap2_2d
- 3.962866634
- umap1_3d
- 0.253867024
- umap2_3d
- -0.808690292
- umap3_3d
- -2.381795145
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.690
- MYC_TARGETS_V1+0.670
- E2F_TARGETS+0.620
- G2M_CHECKPOINT+0.580
- MTORC1_SIGNALING+0.470
- UNFOLDED_PROTEIN_RESPONSE+0.360
- ALLOGRAFT_REJECTION+0.330
- MITOTIC_SPINDLE+0.250
- INFLAMMATORY_RESPONSE+0.240
- ANDROGEN_RESPONSE+0.200
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.360
- APICAL_SURFACE-0.350
- INTERFERON_ALPHA_RESPONSE-0.280
- KRAS_SIGNALING_DN-0.250
- APICAL_JUNCTION-0.240
- MYOGENESIS-0.220
- COAGULATION-0.210
- BILE_ACID_METABOLISM-0.170
- HYPOXIA-0.130
- XENOBIOTIC_METABOLISM-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518152 | — | E | 0.825 |
| 2 | SRR8518311 | — | E | 0.798 |
| 3 | MDT-AP-3322 | Med | Medulloblastoma | 0.796 |
| 4 | TCGA-DK-A1AC-01A-11R-A13Y-07 | — | — | 0.795 |
| 5 | SRR23036890 | — | — | 0.778 |
| 6 | 040cf8cf-7b9d-4873-a51d-ba13bba4201a | — | — | 0.777 |
| 7 | X11368e6c.aeb6.4de4.8e74.436b1cd1846c | — | cohortA1 | 0.773 |
| 8 | SRR12475133 | — | — | 0.770 |
| 9 | MDT-AP-0541 | Med | Medulloblastoma | 0.767 |
| 10 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.690 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.670 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.580 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.140 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |